Skip to Content
MilliporeSigma

C7515

Cannabidiol

Sign In to View Organizational & Contract Pricing

Select a Size

About This Item

Empirical Formula (Hill Notation):
C21H30O2
CAS Number:
13956-29-1
Molecular Weight:
314.46
MDL number:
MFCD04221141
UNSPSC Code:
12352200

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

form

powder

drug control

USDEA Schedule I; regulated under CDSA - not available from Sigma-Aldrich Canada

storage temp.

2-8°C

SMILES string

Oc1c(c(cc(c1)CCCCC)O)C2[C@@H](CCC(=C2)C)C(=C)C

InChI

1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18?/m0/s1

InChI key

QHMBSVQNZZTUGM-ZENAZSQFSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Biochem/physiol Actions

Not psychoactive in humans.

Other Notes

Major component of marijuana from C. sativa

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Repr. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
SLCN1793
SLCG8047
SLCC7915
SLBW5306
SLBR5045V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Alline Cristina Campos et al.
Psychopharmacology, 226(1), 13-24 (2012-09-26)
Cannabidiol (CBD) is a non-psychotomimetic constituent of Cannabis sativa plant that promotes antianxiety and anti-panic effects in animal models after acute systemic or intra-dorsal periaqueductal gray (DPAG) administration. However, the effects of CBD repeated administration, and the possible mechanisms involved
Shaher Duchi et al.
Journal of neuroimmunology, 258(1-2), 32-40 (2013-03-23)
We investigated the efficiency of nasal drug administration as a new non-invasive treatment strategy for MS. Glatiramer Acetate (GA) and GA-Cannabidiol (CBD) combination administered in nasal delivery system (NDS) resulted in a statistically significant decrease of clinical scores and inflammatory
Serena Deiana
Drug testing and analysis, 5(1), 46-51 (2012-10-31)
The medical properties of cannabis have been known for many centuries; its first documented use dates back to 2800 BC when it was described for its hallucinogenic and pain-relieving properties. In the first half of the twentieth century, a number
Michael G Serpell et al.
Journal of neurology, 260(1), 285-295 (2012-08-11)
Sativex is an endocannabinoid system modulator principally containing Δ(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD). During a 6-week randomised controlled trial, Sativex had a clinically relevant effect on spasticity associated with multiple sclerosis (MS). Patients self-titrated oromucosal Sativex to symptom relief or
Celia Oreja-Guevara
Revista de neurologia, 55(7), 421-430 (2012-09-27)
Spasticity remains a prevalent symptom in multiple sclerosis, with a significant associated disability and quality of life impairment. A significant improvement in therapy aimed at reducing multiple sclerosis relapses and modifying its course has been achieved in recent years. Both
View All Related Papers

Related Content

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service